![The financial impact of SBRT for oligometastatic disease: A population-level analysis in Belgium - Radiotherapy and Oncology The financial impact of SBRT for oligometastatic disease: A population-level analysis in Belgium - Radiotherapy and Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/096dab14-12c4-4712-9e4d-aa8853dd23e4/gr1_lrg.jpg)
The financial impact of SBRT for oligometastatic disease: A population-level analysis in Belgium - Radiotherapy and Oncology
![e-mental health innovation and transnational implementation platform North West Europe (eMEN) | Interreg NWE e-mental health innovation and transnational implementation platform North West Europe (eMEN) | Interreg NWE](https://i.ytimg.com/vi/bgXqlryQoj8/maxresdefault.jpg)
e-mental health innovation and transnational implementation platform North West Europe (eMEN) | Interreg NWE
![References in Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial - The Lancet Oncology References in Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/af83f545-54dc-4653-bf8b-befd13f0163a/gr1.gif)
References in Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial - The Lancet Oncology
![Random allocation software for parallel group randomized trials | BMC Medical Research Methodology | Full Text Random allocation software for parallel group randomized trials | BMC Medical Research Methodology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1471-2288-4-26/MediaObjects/12874_2004_Article_84_Fig1_HTML.jpg)